Sean Brady is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1020 Youngs Rd
Williamsville, NY 14221
Telephone
716-961-9900Registry record last updated 3 Oct 2018.
Clinical trials
- Vivio AS (Aortic Stenosis) Algorithm Optimization Study
Sponsor: Ventric Health, LLC
- Vivio AS (Aortic Stenosis) Detection Study
Sponsor: Ventric Health, LLC
- Rapid Non-invasive Detection of Aortic Stenosis
Sponsor: Ventric Health, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- GlaxoSmithKline, LLC.Program year202514 payments
- ARS Pharmaceuticals Operations, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
75.8%Corticosteroid31%Fluticasone Propionate50%Symbicort7%Trelegy Ellipta7%Mometasone Furoate7%Breo Ellipta6%Qvar Redihaler5%Fluticasone Propionate Hfa4%Budesonide-Formoterol Fumarate4%Arnuity Ellipta4%Asmanex4%Breyna2%Part D<11 patientsHistamine-1 Receptor Antagonist16.2%Azelastine Hcl75%Levocetirizine Dihydrochloride21%Desloratadine4%Part D<11 patients+ 8 more classes in this area
Dermatology
7.8%Interleukin-4 Receptor alpha Antagonist6.9%Dupixent Pen78%Dupixent Syringe22%Part D<11 patientsCorticosteroid0.9%Triamcinolone Acetonide100%Part D≥12 patientsMetabolism & gastrointestinal
6.9%Corticosteroid2.9%Prednisone100%Part D≥32 patientsH2 blocker2.4%Famotidine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Bioinformatics guided synthesis of novel antibiotics from previously inaccessible microbial dark matter
Rockefeller University
FY2026$798,670R01AI193146 - Discovery and characterization of synthetic bioinformatic natural product anticancer agents
Rockefeller University
FY2026$423,140R01CA280019 - Discovery of Antibiotics from Soil Microbiomes Using Metagenomics
Rockefeller University
FY2025$678,000R35GM122559
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”